title: Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model.
abstract: In the absence of an adequate small animal model for testing the efficacy of adenovirus-vectored respiratory syncytial virus (RSV) vaccines, a ferret model was established for this purpose. Recombinant adenovirus types 4, 5 and 7 expressing the RSV fusion glycoprotein (F), the attachment glycoprotein (G) or both F and G were constructed previously. These recombinants contain a deletion of a large portion of the E3 region of the respective adenovirus vector. In addition, an Ad7(E3+)F recombinant virus which contains an intact E3 region was constructed to assess whether E3 region functions might enhance vaccine immunogenicity. Evaluation of these viruses in the ferret model demonstrated that Ad4 and Ad5 recombinants, administered intranasally to ferrets, induce stronger seroresponses to RSV than do Ad7 recombinant viruses. Ad7(E3+)F did not show enhanced immunogenicity relative to E3-deleted recombinant viruses. However, measurement of RSV infectivity in nasal washes, following intranasal RSV challenge, showed that five different vaccination regimens, Ad7F/Ad4F, Ad7G/Ad4G, Ad7FG/Ad4FG, Ad4F/Ad7(E3+)F and Ad5F/Ad4F, protected ferrets from RSV infection in a dose-dependent manner.
authors.affiliation: Division of Discovery Research, Wyeth-Ayerst Research, Philadelphia, PA 19101.
authors.forename: K H
authors.initials: KH
authors.lastname: Hsu
authors.forename: M D
authors.initials: MD
authors.lastname: Lubeck
authors.forename: B M
authors.initials: BM
authors.lastname: Bhat
authors.forename: R A
authors.initials: RA
authors.lastname: Bhat
authors.forename: B
authors.initials: B
authors.lastname: Kostek
authors.forename: B H
authors.initials: BH
authors.lastname: Selling
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: A R
authors.initials: AR
authors.lastname: Davis
authors.forename: P P
authors.initials: PP
authors.lastname: Hung
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005289:Ferrets; D005822:Genetic Vectors; D017921:Mastadenovirus / Q000235:genetics*; D008954:Models, Biological; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014760:Viral Fusion Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins; D014765:Viral Vaccines